INOVIQ LTD — Capital/Financing Update 2018

Nov 11, 2018

==> picture [155 x 46] intentionally omitted <==

ENTITLEMENT ISSUE INDICATIVE TIMETABLE

Perth, Australia, 12 November 2018: BARD1 Life Sciences Limited (ASX:BD1) ( BARD1 or the Company ), a biotechnology company developing non-invasive cancer diagnostics, today provides the indicative timetable for its proposed Entitlement Issue.

This follows the Company’s announcement of 8 November 2018 providing details about its Entitlement Issue with Merchant Corporate Advisory Pty Ltd ( Merchant ) acting as Lead Manager.

An Offer Document will be sent offering a 1 for 5 pro rata non-renounceable entitlement issue to eligible shareholders at $0.02 per share to raise approximately $3.3 million. Merchant has made a firm commitment to subscribe and/or place any remaining shares not taken up by eligible shareholders under the Entitlement Issue.

Indicative Timetable: Non-Renounceable Entitlement Issue

Event	Date
Entitlement Issue Offer Document and Appendix 3B released	Monday, 19 November 2018
Trading in Company shares on ex-entitlement basis	Wednesday, 21 November 2018
Record Date for the Entitlement Issue	Thursday, 22 November 2018
Opening Date for the Entitlement Issue	Monday, 26 November 2018
Closing Date for the Entitlement Issue	Monday, 10 December 2018
ASX notified of under-subscriptions	Wednesday, 12 December 2018
Issue and allotment of Entitlement Issue SharesIssue and Allotment of shortfall shares	Monday, 17 December 2018
Normal Trading of Entitlement Issue Shares on ASX expected tocommence	Tuesday, 18 December 2018

Note: Timetable above is Perth, Australia time. The above timetable is indicative only and subject to change. Subject to the requirements of the Corporations Act, the ASX Listing Rules and any other applicable laws, BARD1, in consultation with Merchant, reserves the right to amend this timetable, or withdraw the Entitlement Issue at any time.

Enquiries

For further information in relation to the Entitlement Issue, please contact the Company on (08) 9381 9550 (local call cost within Australia) at any time between 9:00am and 5:00pm (AWST), Monday to Friday (excluding public holidays).

Other information

Offers of new shares will be made under the Entitlement Issue Offer Document ( Offer Document ) to be distributed shortly after the Record Date. Eligible shareholders should carefully consider the Offer Document before deciding to apply for new shares under the Entitlement Issue. Eligible shareholders who wish to acquire new shares will need to complete the application form in or accompanying the Offer Document. A copy of the Offer Document will be available on ASX's website or can be obtained by contacting the Company on the number above.

- ENDS -

FOR MORE INFORMATION PLEASE CONTACT:

Peter Gunzburg Dr Leearne Hinch Chairman CEO E peter@bard1.com E leearne@bard1.com M +61 400 414 416

BARD1 Life Sciences Limited (ABN 58 009 070 384) Registered Office | Suite B1, Tempo Building, 431 Roberts Road, Subiaco WA 6008, Australia P +618 9381 9550 | F +618 9388 7559 | E info@bard1.com | W www.bard1.com

BARD1 | ASX Release

2

ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian-based biotechnology company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1’s proprietary technology platform is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes BARD1 autoantibody tests in development for early detection of breast, ovarian and lung cancers. Additional diagnostic projects will be evaluated for other cancers. The company also has a cancer vaccine project at research-stage for treatment of cancer. BARD1 is committed to transforming the early detection of cancer to save lives. For more information on BARD1, see www.bard1.com.

BARD1 LSL | ASX Release